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Summary
Fanconi anemia (FA) is an autosomal recessive disorder
exhibiting chromosomal fragility, bone-marrow failure,
congenital abnormalities, and cancer. At least eight com-
plementation groups have been described, with group A
accounting for 60%–65% of FA patients. Mutation
screening of the group A gene (FANCA) is complicated
by its highly interrupted genomic structure and hetero-
geneous mutation spectrum. Recent reports of several
large deletions of FANCA, coupled with modest muta-
tion-detection rates, led us to investigate whether many
deletions might occur in the heterozygous state and thus
fail to be detected by current screening protocols. We
used a two-step screening strategy, in which small mu-
tations were detected by fluorescent chemical cleavage
of the FANCA transcript, and heterozygosity for gross
deletions was detected by quantitative fluorescent mul-
tiplex PCR. We screened 26 cell lines from FA comple-
mentation group A for FANCA mutations and detected
33 different mutations, 23 of which were novel. Mu-
tations were observed in all 26 cell lines and included
43 of a possible 52 mutant alleles (83%). Of the mutant
alleles, 40% were large intragenic deletions that removed
up to 31 exons from the gene, indicating that this may
be the most prevalent form of mutation in FANCA. Sev-
eral common deletion breakpoints were observed, and
there was a highly significant correlation between the
number of breakpoints detected in a given intron and
the number of Alu repeats that it contained, which sug-
gests that Alu-mediated recombination may explain the
high prevalence of deletions in FANCA.The dual screen-
ing strategy that we describe may be useful for mutation
screening in other genetic disorders in which mutation-
detection rates are unexpectedly low.
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Introduction
Fanconi anemia (FA; MIM 227650) is an autosomal
recessive disorder associated with a wide range of clinical
features, including progressive bone-marrow failure, di-
verse developmental abnormalities, and a high incidence
of acute myeloid leukemia (Auerbach et al. 1993). FA
cells are hypersensitive to DNA cross-linking agents,
such as diepoxybutane (DEB) and mitomycin C (MMC),
and this provides a valuable laboratory test to support
the clinical diagnosis. The disorder is genetically heter-
ogeneous, with at least eight complementation groups
described to date (Joenje et al. 1997). This indicates that
FA may be caused by a defect in at least eight different
genes, which have been denoted “FANCA”–“FANCH.”
The FANCA, FANCC, and FANCG genes have been
cloned (Strathdee et al. 1992; Fanconi Anemia Breast
Cancer Consortium 1996; Lo Ten Foe et al. 1996; de
Winter et al. 1998), and the FANCD and FANCE genes
have been mapped to chromosomes 3p and 6p, re-
spectively (Whitney et al. 1995; Waisfisz et al. 1999).
FANCA is the most commonly mutated FA gene, ac-
counting for 60%–65% of all cases.
Mutation screening of the FANCA gene is a difficult
task, since the 4.3-kb coding sequence is interrupted by
43 exons (Ianzano et al. 1997), and the mutational spec-
trum is very heterogeneous. More than 100 different
FANCA mutations have been described to date and in-
clude almost all classes of mutations (Fanconi Anemia
Breast Cancer consortium 1996; Lo Ten Foe et al. 1996;
Levran et al. 1997; Savino et al. 1997; Tachibana et al.
1999; Wijker et al. 1999). Mutation-detection rates in
these studies are ∼30%–70%, and there have been sev-
eral recent reports of intragenic deletions in FANCA
(Centra et al. 1998; Levran et al. 1998; Wijker et al.
1999). This led us to postulate that the low mutation-
detection rates might be caused by a high frequency of
intragenic deletions, which would not be detected by the
majority of screening protocols if they occurred in com-
pound heterozygotes whose other mutant allele was a
point mutation. We therefore developed a two-step flu-
orescence-based mutation-screening strategy that would
detect both small mutations in the coding sequence of
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Table 1
Primer Pairs for Six Overlapping RT-PCR Fragments of FANCA Gene
FRAGMENT
1o AND 2o PCR PRIMER PAIRS
(5′r3′)
NUCLEOTIDE
POSITIONa
EXONS
SPANNED
PRODUCT
SIZE
(bp)
PCR CONDITIONS
Annealing
Temperature
(C)
[Mg2] of PCR
(mM)
1 Forward, CCA AGG CCA TGT CCG ACT CG 13–595 1–6 581 60 1.5
Reverse, CAG AAA GCA TGG CCC TGG CGA CG
Forward, GGG TCC CGA ACT CCG CCT CGG GCC 55 1.5
Reverse, TTT CCA GCA GCT CTT GCA GG
2 Forward, GCG CCT CCT GCG AAG CCA TCA G 393–1079 4–12 686 66 1.5
Reverse, CAG CTG GCA GCT CTC GAA TGC
Forward, CAG TCA CCC TGT GCT GCT GAC 64 1.5
Reverse, CGG TAC AGT GAG GTG AGC AG
3 Forward, CAG ATC TGA GAA GAA CTG TGG 893–1627 11–18 734 60 1.5
Reverse, GCC TCC ATG ACG GTG ACT GG
Forward, GGT TCG GAG TGT TCA GTG GAC 60 1.5
Reverse, GCT CAG TAA TGT CCC CAG CTG
4 Forward, GGT TCG GAG TGT TCA GTG GAC 1100–1900 13–21 800 60 5.0
Reverse, CAT CAC GCT GGC TGG GGT CTG
Forward, GTG CAG AGG AGT TGG TTG G 60 4.0
Reverse, CTT CTG GCT TCT CTT CAG CAG
5 Forward, CAT CAT GGT GTT TGA GCA TAC G 1724–3308 19–33 1,584 60 6.7
Reverse, GAA GTC GAC CAT CAG GGA GGG
Forward, GGA GGC CTT ACT ACG TGT CC 60 6.7
Reverse, GCA GTG ATG GGC TGT TCT GCC TG
6 Forward, GCA AGA CCT CAT AGT GCC TC 3093–4486 32–3′ UTR 1,327 60 6.7
Reverse, CGC AAA CGC TGA GTG ACT CG
Forward, CAG ACG GCT CCA GGC TCT GAC 60 6.7
Reverse, CCC ACT AAA GCA GTC GAG G
a Numbering, from the first nucleotide of the initiation codon.
FANCA and heterozygous deletions of one or more ex-
ons. The method was then used to screen the FANCA
gene for mutations in 26 cell lines from patients with
FA who were classified as group A by complementation
analysis. Mutations were observed in all 26 cell lines
and included a high frequency of intragenic deletions,
some of which removed 130 exons from the FANCA
gene. This strategy may have general application for mu-
tation screening in other disorders.
Patients and Methods
Patients
Patients were ascertained by EUFAR (European Con-
certed Action on Fanconi Anemia Research), and blood
samples were obtained with informed consent. Twenty-
six unrelated FA patients had been diagnosed previously,
on the basis of their clinical presentation and their cel-
lular hypersensitivity to mitomycin C (MMC) or di-
epoxybutane (DEB). Lymphoblastoid cell lines were es-
tablished and tested by complementation analysis to
identify group A patients, as described elsewhere (Joenje
et al. 1995).
Methods
RNA Extraction and Reverse-Transcriptase PCR (RT-
PCR).—Total RNA was extracted from lymphoblasts, as
described elsewhere (Chomczynski and Sacchi 1987).
From each cell line, 2.5 mg of total RNA was reverse
transcribed by use of 25 ng each of the following specific
primers, in order to ensure transcription of the entire
coding sequence: 1727R (5′-GCCTCCATGACGGTGA-
CTGG-3′), 3′ R1 (5′-GCTCCAGGTCAGCTACCATC-
TCCTGC-3′), 3494R (5′-GAAGTCGACCATCAGGG-
AGGG-3′), and RU4955R (5′-CAGAGCTGGACTTT-
GCCTGT-3′).
These primers were multiplexed in a single reaction
and heated for 10 min at 65C. Then, to each patient
sample, 1 # reverse transcriptase buffer, 10 mM DTT,
500 mM each dNTP, 40 U RNase inhibitor, and 200 U
MMLV reverse transcriptase (Gibco BRL) was added,
incubated at 42C for 1 h, and heated at 95C for 3 min
to destroy the enzyme. The full coding sequence was
amplified in six overlapping fragments, with 200 bp
of overlapping sequence between each pair of fragments.
A primary PCR was carried out for each of the six frag-
ments, with 0.4 mM each of forward and reverse primer
(for primer sequences and conditions, see table 1), 500
1332 Am. J. Hum. Genet. 65:1330–1341, 1999
mM each dNTP, 1 # Taq DNA polymerase buffer (67
mM Tris-HCl, pH 8.8, 16.6 mM (NH4)2SO4, X mM
MgCl2, where X is 1.5–6.7, 170 mg BSA/ml, 10 mM b-
mercaptoethanol), 1 ml cDNA, and 1.5 U (Promega) Taq
polymerase. PCR conditions were an initial denaturation
step at 94C for 5 min, followed by 30 cycles of dena-
turation at 94C for 10 s, annealing for 30 s, and ex-
tension for 1 min at 72C for each kilobase of fragment
size. A final extension for 5 min at 72C was added.
Nested PCR was then carried out by addition of 1 ml of
the primary PCR product to a secondary PCR mix, as
before (see table 1), but with the inclusion of 0.3 ml of
one of three different fluorescently-labeled dUTP solu-
tions: TAMRA-yellow, R6G-green, or R110-blue (PE
Biosystems). Secondary products were then electropho-
resed in a 1.5% agarose gel to check for aberrantly sized
bands, which were Geneclean-purified and sequenced by
use of the ABI 377 DNA sequencer. Full-size fragments
were used directly for fluorescent chemical cleavage of
mismatch (FCCM) analysis (see below). Probes used for
FCCM were amplified from the FANCA cDNA (Lo Ten
Foe et al. 1996), as for patient cDNA, but with use of
biotinylated primers as well as fluorescent dUTPs.
Solid-Phase FCCM Detection.—This procedure was
based on the use of chemical cleavage to detect mis-
matched bases in heteroduplexes formed between wild-
type and patient DNA (Cotton et al. 1988; Ellis et al.
1998). The original method has been modified to a solid-
phase, fluorescence-based protocol that allows rapid and
sensitive detection of point mutations and other small
lesions (Rowley et al. 1995). Two microliters of bioti-
nylated, fluorescently labeled probe was gel-purified and
added to 2 ml fluorescently labeled target in 1 # hy-
bridization buffer (0.3 M NaCl, 100 mM Tris-HCl, pH
8.0) in a total volume of 30 ml. This was denatured for
5 min at 95C, then held for 60 min at 65C to form
heteroduplexes, which could be stored at 4C for several
hours. Streptavidin-coated beads (Dynal) were treated
by taking 10 ml of beads for every patient sample DNA
and washing twice in 1 # binding and washing buffer
(5 mM Tris-HCl, pH 7.5, 0.5 mM EDTA, 1 M NaCl),
before resuspension in 20 ml 2 # binding and washing
buffer. This 20-ml bead suspension was then added to
the hybrid DNA and resuspended. After 15 min the su-
pernatant was removed from the beads by use of a mag-
net (Promega). The beads with the bound DNA were
then resuspended in 20 ml hydroxylamine solution (4 M
hydroxylamine hydrochloride, 2.3 M diethylamine) and
incubated at 37C for 2 h or were resuspended in os-
mium tetroxide solution (0.4% OsO4, 2% pyridine) and
incubated at room temperature for 15 min. The super-
natant was removed from the beads as before, and the
beads were washed in binding and washing buffer before
resuspension in 5 ml piperidine solution (2 M piperidine
in formamide plus dextran blue dye) and heating at 90C
for 15 min. Two microliters of the supernatant was
loaded on a 6% acrylamide denaturing gel and electro-
phoresed for 5 h on an ABI 377 DNA sequencer. Data
were collected and analyzed by means of Genescan 2.0
ABI 377 software (see electrophoretogram, in fig. 1).
Quantitative Fluorescent Multiplex PCR.—Genomic
DNA was prepared from lymphoblastoid cell lines by
salt/chloroform extraction, as described elsewhere (Gib-
son et al. 1996). DNA samples were then incubated at
55C for 1 h; half of this sample was taken to determine
the concentration, and the remainder was diluted to 25
ng/ml for the PCR. Three fluorescently labeled multiplex
PCR assays were used to amplify exons from the FANCA
and FANCC genes. The FANCC gene was used as an
external control, since cell lines were classified as FA-A
and no deletions have been described in extensive screen-
ing of the FANCC gene (Verlander et al. 1994; Gibson
et al. 1996). Multiplex assay 1 amplified exons 10–12,
31, and 32 from the FANCA gene and exons 5 and 6
from the FANCC gene. Multiplex assay 2 amplified ex-
ons 5, 17, 35, and 43 from the FANCA gene and exons
5 and 6 from the FANCC gene. Multiplex assay 3 am-
plified exons 21 and 27 from the FANCA gene and exons
5 and 6 from the FANCC gene. All forward primers
were labeled with either the fluorescent phosphoramidite
6-FAM or HEX dyes (PE Biosystems). Primer sequences,
fluorescent dyes used, and sizes of products are shown
in table 2. PCR amplifications were performed in 25 ml
reactions with 125 ng DNA, 1# Taq DNA polymerase
buffer (as used for RT-PCR), and 200 mM each dNTP.
Of each of the primer pairs, 0.2 mM was used for each
of the three multiplexes, apart from 0.4 mM for FANCA
exons 5, 11, 12, and 31. After an initial denaturation
at 94C for 3 min, 1.5 U Taq DNA polymerase (Pro-
mega) was added (hot start), and 18 PCR cycles of 93C
for 1 min, annealing for 1 min at either 60C (multiplex
1 and 3) or 58C (multiplex 2), and extension for 2
minutes at 72C were performed, followed by a final
extension for 5 min at 72C. Only 18 PCR cycles were
performed, to keep the reactions within the exponential
phase of PCR (see Yau et al. 1996). An aliquot of the
PCR product (4 ml) was added to 3.5 ml formamide load-
ing buffer (95% formamide in 1# TBE and 5 mg dex-
tran blue/ml) and 0.5 ml internal lane size standard (Ge-
nescan-500 Rox; PE Biosystems). The samples were
denatured for 5 min at 94C and electrophoresed on a
5% denaturing polyacrylamide gel at 45 W for 6 h on
an ABI 373 fluorescent DNA sequencer. Data were then
analyzed by means of Genescan and Genotyper soft-
ware, to obtain electrophoretograms for each sample.
The position of the peaks indicates the size (in bp) of
the exons amplified, and the areas under the peaks in-
dicate the amount of fluorescence from the product. Fig-
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Figure 1 Electrophoretogram showing FCCM analysis of fragment 3 in patient BD237. Both this sample and a control show alternative
splicing of exon 14. Rox250 W marker.0 = M
ure 2 shows an example of the electrophoretograms ob-
tained. On one gel, 24 samples could be amplified and
electrophoresed. At least four control DNAs were always
included on each gel. The copy number of each exon
amplified was established by importing the peak area
values into an Excel spreadsheet and calculating a dos-
age quotient for each exon relative to all the other am-
plified exons in patients and controls (for an example
see table 3). Peak areas from two control samples with
approximately equal values were chosen, and the dosage
quotient was calculated from them; values are typically
within the range 0.77–1.25 (Yau et al. 1996). An average
peak area of these controls was taken and compared
with the peak area of the exon from the patient samples.
As an example, in patient EUFA444 the dosage quotient
for FANCA exon 10 and FANCC exon 5 is given by:
DQ FANCA exon 10/FANCC exon 5 and is calculated
by: [sample FANCA exon 10 peak area/sample FANCC
exon 5 peak area] [control FANCA exon 10 peak area/
control FANCC exon 5 peak area] = [1857/5301]/[6034/
8180] = 0.47. After assessment of which exons were
most frequently deleted from FANCA, multiplex 4 was
developed (see table 2), with exon 1 of the myelin protein
zero gene as the external control.
Results
A two-step mutation-screening strategy was devised
to detect both small mutations—such as single-base sub-
stitutions—and heterozygous deletions of one or mul-
tiple exons of the FANCA gene. In the first step, the
entire coding region was amplified by RT-PCR, and the
fragments were sized on agarose gels. Aberrantly sized
fragments were characterized by automated sequencing.
The loss of an exon or the incorporation of intronic
sequence led to the investigation of genomic DNA for
splice-site mutations, whereas the loss of multiple exons
revealed the presence of intragenic deletions. Full-length
transcripts were screened by FCCM for nucleotide sub-
stitutions or small deletions and insertions. In the second
step, genomic DNA was used to screen for deletions of
one or more exons, by a fluorescent quantitative mul-
tiplex dosage assay that was based on an approach that
we had originally developed to test for deletion and du-
plication carriers in Duchenne muscular dystrophy (Yau
et al. 1996). In this assay, several exons of the FANCA
gene were coamplified with two control exons from an-
other locus, by use of fluorescently labeled primers, and
the products were analyzed on an ABI 373 DNA-frag-
Table 2
PCR Primer Sets for Multiplex Dosage Assays
Exon
Primers
(5′r3′)
Size
(bp)
Multiplex 1:
FANCA:
Exon 10 Forward, GAT TGT AGA AGT CTT GAT GGA TGT G 259
Reverse, ATT TGG CAG ACA CCT CCC TGC TGC
Exon 11 Forward, GAT GAG CCT GAG CCA CAG TTT GTG 301
Reverse, AGA ATT CCT GGC ATC TCC AGT CAG
Exon 12 Forward, CCA CAA CTT TTT GAT CTC TGA CTT G 224
Reverse, GTG CCG TCC ACG GCA GGC AGC ATG
Exon 31 Forward, CAC ACT GTC AGA GAA GCA CAG CCA 205
Reverse, CAC GCG GCT TAA ATG AAG TGA ATG C
Exon 32 Forward, CTT GCC CTG TCC ACT GTG GAG TCC 369
Reverse, CTC ACT ACA AAG AAC CTC TAG GAC
FANCC:
Exon 5 Forward, CTG ATG TAA TCC TGT TTG CAG CGT G 186
Reverse, TCC TCT CAT AAC CAA ACT GAT ACA
Exon 6 Forward, GTC CTT AAT TAT GCA TGG CTC TTA G 293
Reverse, CCA ACA CAC CAC AGC CTT CTA AG
Multiplex 2:
FANCA:
Exon 5 Forward, ACC TGC CCG TTG TTA CTT TTA 250
Reverse, AGA ACA TTG CCT GGA ACA CTG
Exon 17 Forward, CCC TCC ATG CCC ACT CCT CAC ACC 207
Reverse, AAA AGA AAC TGG ACC TTT GCA T
Exon 35 Forward, GAT CCT CCT GTC AGC TTC CTG TGA G 315
Reverse, GCA TTT TCC CTG AGA TGG TAA CAC C
Exon 43 Forward, GCC TGG CTG GCA ATA CAA CTC GAC 223
Reverse, GGC AGG TCC CGT CAG AAG AGA TGA G
FANCC:
Exon 5 Forward, CTG ATG TAA TCC TGT TTG CAG CGT G 186
Reverse, TCC TCT CAT AAC CAA ACT GAT ACA
Exon 6 Forward, GTC CTT AAT TAT GCA TGG CTC TTA G 293
Reverse, CCA ACA CAC CAC AGC CTT CTA AG
Multiplex 3:
FANCA:
Exon 21 Forward, CAG GCT CAT ACT GTA CAC AG 335
Reverse, CAC CGG CTT GAG CTG GCA CAG
Exon 27 Forward, CAG GCC ATC CAG TTC GGA ATG 285
Reverse, CCT TCC GGT CCG AAA GCT GC
FANCC:
Exon 5 Forward, CTG ATG TAA TCC TGT TTG CAG CGT G 186
Reverse, TCC TCT CAT AAC CAA ACT GAT ACA
Exon 6 Forward, GTC CTT AAT TAT GCA TGG CTC TTA G 293
Reverse, CCA ACA CAC CAC AGC CTT CTA AG
Multiplex 4:
FANCA:
Exon 5 Forward, ACC TGC CCG TTG TTA CTT TTA 250
Reverse, AGA ACA TTG CCT GGA ACA CTG
Exon 11 Forward, GAT GAG CCT GAG CCA CAG TTT GTG 301
Reverse, AGA ATT CCT GGC ATC TCC AGT CAG
Exon 17 Forward, CCC TCC ATG CCC ACT CCT CAC ACC 207
Reverse, AAA AGA AAC TGG ACC TTT GCA T
Exon 21 Forward, CAG GCT CAT ACT GTA CAC AG 335
Reverse, CAC CGG CTT GAG CTG GCA CAG
Exon 31 Forward, CAC ACT GTC AGA GAA GCA CAG CCA 268
Reverse, CCC AAA GTT CTG GGA TTA CAG GCG TG
Myelin protein zero:
Exon 1 Forward, CAG TGG ACA CAA AGC CCT CTG TGT A 389
Reverse, GAC ACC TGA GTC CCA AGA CTC CCA G
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Table 3
Statistical Profile of FANCA Dosage Multiplex 1
EXON
PEAK AREA IN
DOSAGE QUOTIENT
IN
Control EUFA444a
FANCC
Exon 5
FANCC
Exon 6
Control:
FANCC exon 5 8180 5301 ) .99
FANCC exon 6 4490 2949 1.01 )
Test:
FANCA exon 10 6034 1857 .47 .47
FANCA exon 11 16967 5392 .49 .48
FANCA exon 12 9068 3256 .55 .55
FANCA exon 31 5466 3110 .88 .87
FANCA exon 32 5838 3887 1.03 1.01
a Heterozygous for a deletion of exons 10–12. For a sample cal-
culation, see Methods subsection.
Figure 2 Electrophoretograms showing a deletion carrier of exons 10–12, detected with FANCA gene dosage multiplex 1
ment analyzer. Heterozygous deletions were detected by
a reduction in peak area of FANCA exons relative to
those in controls. The two-step strategy was used to
screen for mutations in RNA and DNA from 26 FA-A
cell lines.
Aberrant FANCA Transcripts
RT-PCR analysis of the FANCA coding region in six
overlapping fragments detected abnormally sized tran-
scripts, in seven patients, that were found to be either
splice-site mutations or intragenic deletions (all of the
mutation data in this study are summarized in table 4).
Patients EUFA123 and EUFA137 had reductions in size
for fragments 2 and 4, respectively; sequencing of their
genomic DNA revealed the splice-site mutations
IVS62ArG and IVS163ArC. In patient EUFA779,
fragment 4 contained an insertion of 90 bp of intron 15
sequence upstream of exon 16, and sequencing of ge-
nomic DNA around exon 16 from this patient revealed
the splice-site mutation IVS151GrT. The intronic in-
sertion resulted from the use of a cryptic splice-site in
intron 15 and contained a stop codon (TGA) that would
cause premature termination of translation. In patient
EUFA755, fragment 4 showed no full-length product but
did show two smaller products, which were revealed by
sequencing to be two different deletions, of exons 15–17
and exons 16–20. PCR analysis of genomic DNA from
this patient showed homozygous deletions of exons 16
and 17, which resulted from the overlap of the two in-
tragenic deletions. In patients EUFA006 and EUFA417,
reduced-size products in fragment 4 were shown, by se-
quencing, to be deletions of exons 15–20 and 16–17,
respectively. Heterozygosity for deletions in this region
was confirmed by quantitative PCR (see below). In pa-
tient EUFA854, a reduction in fragment 5 was a deletion
of exons 29–31, again confirmed by quantitative PCR.
A high degree of alternative splicing of the FANCA
gene was also detected. Exon 14 was commonly spliced
out from fragment 3, and exon 30 from fragment 5.
Both of these splicing events were seen in RNA prepared
from lymphoblastoid control cell lines. An example of
the shorter fragment produced in patients and controls,
as a result of splicing out of exon 14, is shown in the
electrophoretogram from the FCCM analysis in figure
1. Various other alternative splicing events were seen
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Table 4
Mutations Detected in the FANCA Gene of FA Patients
Patient Mutation 1 Effect Exon(s)
Method of
Detection Mutation 2 Effect Exon(s)
Method of
Detection
EUFA353 154CrTa R52X 2 FCCM *5′ UTR–522*del Deletion *5′ UTR–5* Dosage
BD237 *5′ UTR–522*del Deletion *5′ UTR–5* Dosage 1115–1118deld Frameshift 13 FCCM
EUFA1030 *427–522*del Deletion *5* Dosage 987–990delb Frameshift 11 Dosage
EUFA444 *5′ UTR–1900*del Deletion *5′ UTR–21* Dosage 1115–1118deld Frameshift 13 FCCM
EUFA750 *5′ UTR–3066del Deletion *5′ UTR–31 Dosage 3788–3790dela,b 1263delF 38 FCCM
BD812 *5′ UTR–3066del Deletion *5′ UTR–31 Dosage Not detected
EUFA651 523–1359del Deletion 6–14 Dosage Not detected
EUFA123 IVIS62ArGa Del13AA I6 RT-PCR Not detected
EUFA186 597–1826del Deletion 7–20 Dosage Not detected
BD220 862GrT E288X 10 FCCM Homozygote
BD255 862GrT E288X 10 FCCM 4015delC Frameshift 41 FCCM
EUFA056 1007–3066del Deletion 12–31 Dosage 1827–2778del Deletion 21–28 Dosage/exon PCR
EUFA763 1191–1194dela Frameshift 13 FCCM 3971CrT P1324L 40 FCCM
EUFA755 1360–1626del Deletion 15–17 Dosage/RT-PCR 1471–1826del Deletion 16–20 Dosage/RT-PCR
EUFA006 1360–1826delc Deletion 15–20 RT-PCR/Dosage 3788–3790dela,b 1263delF 38 FCCM
EUFA779 IVS151GrT Splicing 16 RT-PCR Not detected
EUFA417 1471–1626deld,e Deletion 16–17 RT-PCR/Dosage 3788–3790dela,b 1263delF 38 FCCM
EUFA137 IVS163ArC Exon skip i16 RT-PCR Not detected
EUFA057 1771CrTb R591X 19 FCCM Homozygote
EUFA134 1792GrAa D598N 20 FCCM 1627–1900del Deletion 18–21 Dosage
EUFA854 2779–3066del Deletion 29–31 Dosage/RT-PCR Not detected
EUFA583 *2982–4365del Deletion *31–43 Dosage Not detected
BD32 3329ArC H1110P 33 FCCM Homozygote
EUFA413 3403–3405del 1135delF 34 FCCM Not detected
BD460 3629–3630insT Frameshift 37 FCCM Homozygote
EUFA097 3786CrG F1262L 38 FCCM 4080GrC M1360I 41 FCCM
NOTE.—An asterisk (*) denotes that the deletion endpoint is undefined.
a Previously described by Wijker et al. (1999).
b Previously described by Levran et al. (1997).
c Previously described by Lo Ten Foe et al. (1996).
d Previously described by Fanconi Anaemia/Breast Cancer Consortium (1996).
e Previously described by Levran et al. (1998).
that, on sequencing, either produced mixed unreadable
sequence or, by the detection of a mutation elsewhere in
the gene, were excluded as the pathogenic mutation. For
example, a transcript lacking exons 21–26 was seen in
patient BD255, but this deletion was also present in
controls, and both mutant alleles were found in other
RT-PCR fragments from this patient.
FCCM Analysis
A total of 18 mutant alleles were detected by screening
full-length transcripts from the six overlapping frag-
ments of the FANCA coding region by FCCM, and these
are listed in table 4. An example of the electrophoretic
profiles produced by this analysis is shown in figure 1.
Since PCR products are internally labeled by incorpo-
ration of fluorescent dUTP, the sizes of the two cleavage
products accurately define the position of the mutation,
which is then confirmed by sequencing of genomic DNA
from the region. All 18 mutant alleles were detected by
modification with hydroxylamine, which modifies only
mismatched C bases. However, since both the probe and
target were fluorescently labeled, and since biotinylated
forward and reverse primers were used for each frag-
ment, mutations such as ArG are detected as a mis-
matched C on the reverse strand. Although modification
was also carried out with osmium tetroxide, no further
mutations were found. The use of hydroxylamine alone
has been shown to detect 95% of all mutations (Row-
ley et al. 1995; Ellis et al. 1998). The procedure also
detected numerous coding-sequence polymorphisms, in-
cluding 1143GrT, 1235CrT, 1290GrA, 1501GrA,
1927CrG, 2151GrT, 2426GrA, and 4152GrC. These
have been excluded as pathogenic mutations in other
studies (Levran et al. 1997; Savino et al. 1997; Wijker
et al. 1999; Fanconi Anemia Mutation Database) and
have served as useful positive controls for the chemical
cleavage.
Quantitative Fluorescent Multiplex PCR
Three separate quantitative multiplex PCR assays
were established that collectively screened for hetero-
zygous deletions in 11 exons across the FANCA gene.
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Figure 3 Mutations detected in the FANCA gene in patients with FA. The figure is a schematic representation of the 43 exons of the
FANCA gene. Novel mutations are shown in boldface. Large deletions are indicated by horizontal lines, which are dotted where endpoints are
undefined.  = Exons included in dosage multiplex assays.
Exons were selected on the basis of robust amplification
in multiplex PCR and by noting which exons were most
frequently deleted as the work proceeded, and they in-
cluded 5, 10–12, 17, 21, 27, 31, 32, 35, and 43. In these
assays, the peak area of each exon is measured against
all other exons in the multiplex, including two exons
from a different locus, to produce a series of dosage
quotients (for details, see Methods subsection). A typical
electrophoretogram and a typical statistical profile of
this analysis are shown in figure 2 and table 3, respec-
tively. Genomic DNA from the 26 cell lines was used to
screen for intragenic deletions by use of these three mul-
tiplex PCR reactions. A total of 17 large deletions were
detected, which removed 1–31 exons of the FANCA
gene (see table 4 and fig. 3). The multiplex assay also
detects microdeletions within an exon, by means of size
discrimination; in this way, patient EUFA1030 was
found to be heterozygous for a 4-bp deletion in exon
11. The deletion data in figure 3 indicate that all dele-
tions detected in the FA-A patients included one or more
of the following five exons: 5, 11, 17, 21, and 31. A
further multiplex was therefore designed that includes
these five exons and exon 1 of the Myelin protein zero
gene as an external control (see Methods subsection and
table 2). This one multiplex, instead of the three other
assays, can now be used for FANCA deletion screening.
RT-PCR analysis and polymorphic marker typing
were used to map the approximate endpoints of the de-
letions. In six patients the most 5′ exon deleted was exon
5 (table 4). RT-PCR assays were therefore designed to
amplify from exon 1 of the gene to a downstream exon
known, from the dosage assay, to be present. These as-
says did not produce smaller transcripts, which sug-
gested that the deletion endpoints extended upstream of
the primer site in exon 1. A PCR was then carried out
on genomic DNA, with a primer upstream of the
FANCA 5′ UTR and a primer 3′ to the deletion, but no
products were detected, again suggesting that the dele-
tion extended beyond the promoter. The extent of these
deletions was further investigated by typing the micro-
satellite polymorphic marker D16S3407, which is lo-
cated 16 kb upstream of the 5′ UTR of the gene (Whit-
more et al. 1998), in these patients and, if available, in
parental samples. Since five of the six patients typed were
homozygous for the marker (which has a heterozygosity
of .77), the deletions may extend even farther upstream
of the FANCA gene. This was confirmed in two of these
five patients (EUFA353 and BD812), since parental
DNA was available and informative with this marker,
and both patients showed lack of inheritance of the pa-
rental allele that was linked to the deletion. The end-
points of deletions in EUFA cell lines 134, 186, 417,
651, 755, and 854 were defined by nested RT-PCR with
primers outside the exons found to be deleted by the
dosage assays followed by sequencing of the products
(see table 4). The precise breakpoints of the exon 16–17
deletion in EUFA417 are different from the two deletions
of these exons reported by Levran et al. (1998), since
primers for those breakpoints did not generate the ex-
pected PCR products. In EUFA056, the endpoints of one
deletion could be deduced as exon 21–28 since exons
21 and 28 were homozygously deleted and exons 20 and
29 were present; the other mutant allele in this patient
is a deletion of exons 12–31, which was precisely defined
in the dosage assay and overlaps the exon 21–28 dele-
tion. The endpoint of the deletion in EUFA583 could
not be defined, since the deletion extended beyond the
3′ UTR of the gene.
The analysis of FANCA deletion endpoints in this se-
ries of patients suggests at least four common break-
points; there were four breaks in intron 31, four in intron
20, and up to five in the region 5′ to the gene (table 4).
In view of the involvement of Alu-repeat elements in the
generation of three published FANCA deletions (Centra
et al. 1998; Levran et al. 1998), we searched the com-
plete genomic sequence of the FANCA gene (AC005565,
AC005567, and AC005360) for Alu repeats and com-
pared the number of repeats with the number of known
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Figure 4 FANCA deletion breakpoints and Alu repeats. The number of deletion breakpoints includes those defined in this study and in
the study by Wijker et al. (1999). The number of Alu-repeat elements shown for the 5′ end of the gene is for the sequence from the microsatellite
D16S3407 to the initiation codon of FANCA. The number for the 3′ end is for 3 kb of sequence downstream of the stop codon.
deletion breakpoints that we have detected in this and
a previous study (Wijker et al. 1999). The results of this
analysis (fig. 4) show that the most common breakpoints
all occur in genomic regions that contain four or more
Alu repeats and that none of the breakpoints occur in
introns with fewer than two repeats. The presence of a
deletion breakpoint correlated strongly with the pres-
ence of an Alu repeat ( , Fisher’s exact test), andP ! .001
linear regression analysis showed a highly significant
correlation between the number of Alu repeats and the
number of breakpoints detected ( ).5P = 2.8# 10
FANCA Mutation Spectrum
A total of 33 different mutations were identified in
this study, 23 of which were novel (fig. 3). This very
heterogeneous spectrum included three splice-site mu-
tations, two in-frame deletions of single–amino acid co-
dons, three nonsense mutations, five missense mutations,
five microdeletions or insertions that caused frameshifts,
and 15 different large intragenic deletions (table 4 and
fig. 3). The large intragenic deletions accounted for 17
(40%) of the 43 mutant alleles, making them by far the
most common class of mutation in the FANCA gene.
No single mutation was common, but E288X was found
in two unrelated British patients, and 1263delF, which
was originally described by Levran et al. (1997), was
found in two French patients and one German patient.
The pathogenic status of the five missense mutations was
verified initially by confirming their cosegregation with
the disease phenotype in the family and their absence in
100 ethnically matched control chromosomes. D598N
is a nonconservative substitution that alters an amino
acid residue that is conserved in the mouse Fanca gene
(H. van de Vrugt, personal communication). H1110P is
a nonconservative change that is not conserved in the
mouse but has been shown to be nonfunctional in a
cellular complementation assay (Kupfer et al. 1999). The
other three (F1262L, P1324L, and M1360I) are con-
servative changes, but the altered residues are all con-
served in the mouse. The sensitivity of the two-step mu-
tation-screening assay can be deduced from the fact that
at least one mutation was detected in all 26 FA-A cell
lines tested, and 43 (83%) of the possible 52 mutant
alleles were found.
Discussion
The modest detection rates reported from mutation
screening of the FANCA gene, coupled with several re-
ports of intragenic deletions (Centra et al. 1998; Levran
et al. 1998; Wijker et al. 1999), led us to investigate
whether these findings were connected. We therefore de-
vised a mutation-screening protocol that would detect
both small mutations, such as point mutations and mi-
crodeletions or insertions, and gross deletions that were
present in the heterozygous state. The protocol was used
to screen RNA and DNA from 26 cell lines that had
been selected solely on the basis of their having been
shown, by complementation analysis, to be FA group A.
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The quantitative PCR assay detected 17 deletions of the
FANCA gene in these cell lines, which accounted for
40% of the mutant alleles observed. This result suggests
that gross deletions of one or more exons of the FANCA
gene are the most common form of mutation in this gene.
The endpoints of 10 of the 17 deletions were established
by RT-PCR and sequencing (table 4 and fig. 3). In six
of the other deletions, genomic PCR with a primer from
the FANCA 5′ UTR showed that the deletion is likely
to extend upstream of the gene, and five patients were
apparently homozygous for a highly informative micro-
satellite polymorphism, D16S3407, that lies 16 kb up-
stream of the initiation codon (Whitmore et al. 1998).
This suggests that the deletion extends beyond this
marker in at least some of these, as confirmed by family
studies with this marker in two cases. In one of these
cases, BD812, the deletion extends to exon 31 and must
therefore remove 80 kb of DNA. The remaining de-
letion extends 3′ to the last exon of FANCA, exon 43.
The presence of several common breakpoints in this se-
ries of deletions and the evidence that three fully char-
acterized deletions of FANCA appear to result fromAlu-
mediated recombination (Centra et al. 1998; Levran et
al. 1998) led us to compare the breakpoints of all the
deletions that we have detected in this and another study
(Wijker et al. 1999) with the location of Alu repeats in
FANCA that were obtained from its complete genomic
sequence. This analysis (fig. 4) revealed a highly signif-
icant correlation between the breakpoints and the pres-
ence of multiple repeats and provides strong experi-
mental support for the suggestion that this may be a
common method for the generation of FANCA deletions
(Centra et al. 1998; Levran et al. 1998). The frequency
of these repeats in FANCA would then explain the high
prevalence of gross deletions in its mutation spectrum.
It might also indicate a higher mutation rate for FANCA
as compared to other FA genes, which would explain
why FA-A is by far the most common complementation
group in this disorder (Joenje et al. 1997).
The two-step mutation-screening protocol that we de-
veloped in this study detected at least one mutation in
all 26 cell lines screened and 43 (83%) of the expected
52 mutant alleles. This compares well with the results
of other published studies. Savino et al. (1997) detected
mutations in only 29% of Italian patients with FA, al-
though complementation analysis showed that the prev-
alence of FA-A in Italy was 190% (Savoia et al. 1996).
Levran et al. (1997) found mutations in 69% of patients
unselected for complementation group, but 35% of these
mutations were amino acid substitutions of unknown
pathogenic status, and Wijker et al. (1999) detected mu-
tations in 49% of probable FA-A patients. The highest
detection rate was reported by Tachibana et al. (1999),
who found mutations in 12 of 15 Japanese FA patients
by direct sequencing; 22 (73%) of a possible 30 mutant
alleles were detected. None of these studies included
quantitative analysis of FANCA exon copy number. Our
finding that 40% of the mutant alleles detected in 26
FA-A cell lines were heterozygous deletions of multiple
exons suggests that mutation-detection rates can be sub-
stantially improved by incorporation of a quantitative
assay into screening protocols. Since all of the mutations
observed in our study involved one or more of exons 5,
11, 17, 21, and 31, we replaced the three multiplex PCRs
that we developed initially by a single multiplex that
incorporated these five exons and a control exon from
an unrelated gene. This could serve as a useful and rapid
initial molecular screen for FA in patients of unknown
complementation group or of uncertain diagnosis.
The combination of FCCM and dosage analysis failed
to detect 9 (17%) of a possible 52 mutant alleles. There
are several possible explanations for this. The undetected
mutations could be intragenic deletions of exons that
were not included in the dosage multiplexes; collectively,
the three multiplexes screened only 11 of the 43 exons,
and the RT-PCR analysis would not detect all such de-
letions—for a variety of reasons, including the “noise”
created by numerous alternative splicing events. The un-
detected mutations could also be complex genomic re-
arrangements, such as duplications or inversions, or they
might conceivably be located in regions of the gene that
were not screened in our protocol, such as the promoter
or 3′ UTR. Finally, a small proportion of point mutations
are not detected by FCCM if they are located in partic-
ular sequence contexts (Rowley et al. 1995; Ellis et al.
1998). Ultimately, no mutation-screening protocol is
perfect, and a judgment has to be made as to whether
a large amount of additional effort and expense can be
justified in order to achieve 100% sensitivity of
detection.
The very heterogeneous nature of the mutation spec-
trum in the FANCA gene is exemplified in this study:
33 different mutations were found in the 26 patients, of
which 23 were novel mutations. The most interesting
mutations, from the perspective of an attempt to describe
the functional architecture of the FANCA protein, are
those which do not cause premature termination of
translation, such as the missense mutations and the de-
letions of single–amino acid codons. Almost all of these
are clustered in the carboxy-terminal region of amino
acid residues 1110–1360 (table 4), which may reflect the
presence of an important functional domain involved in
protein-protein interactions or in transport to the nu-
cleus. In this group, only H1110P has, as yet, been con-
firmed as disrupting the function of the FANCA protein
(Kupfer et al. 1999). Introduction of the others into the
wild-type cDNA is in progress, in order to test them for
absence of functional complementation.
Finally, the high sensitivity of the two-step screening
procedure described in this article suggests that it may
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be usefully applied to mutation detection in other dis-
orders. The utility of the multiplex quantitative assay
for detection of deletions in the heterozygous state could
be exploited to search for gross deletions in autosomal
dominant disorders such as familial breast cancer, since
evidence for such deletions in the BRCA1 gene is begin-
ning to emerge (Puget et al. 1999). Also, in view of the
general importance of Alu-mediated deletions in human
genetic disorders (Purandare and Patel 1997) and the
increasing availability of the complete genomic sequence
of human genes, an initial electronic search for the lo-
cation and density of such repeats may be a useful prel-
ude to the design of mutation-screening strategies for a
specific gene.
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